IQVIA Holdings
Market Cap
US$28.9b
Last Updated
2020/06/05 05:41 UTC
Data Sources
Company Financials +
Executive Summary
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
Rewards
Risk Analysis
Snowflake Analysis
Reasonable growth potential with questionable track record.
Similar Companies
Share Price & News
How has IQVIA Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IQV's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
1.1%
IQV
1.0%
US Life Sciences
2.9%
US Market
1 Year Return
9.0%
IQV
19.6%
US Life Sciences
8.9%
US Market
Return vs Industry: IQV underperformed the US Life Sciences industry which returned 19.6% over the past year.
Return vs Market: IQV matched the US Market which returned 8.9% over the past year.
Shareholder returns
| IQV | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.1% | 1.0% | 2.9% |
| 30 Day | 12.8% | 9.3% | 10.6% |
| 90 Day | 11.1% | 16.0% | 5.1% |
| 1 Year | 9.0%9.0% | 19.9%19.6% | 11.4%8.9% |
| 3 Year | 75.5%75.5% | 83.9%82.5% | 34.3%25.4% |
| 5 Year | 115.9%115.9% | 130.4%127.5% | 60.7%42.7% |
Price Volatility Vs. Market
How volatile is IQVIA Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Can We See Significant Institutional Ownership On The IQVIA Holdings Inc. (NYSE:IQV) Share Register?1 month ago | Simply Wall St
Results: IQVIA Holdings Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts1 month ago | Simply Wall St
How Should Investors React To IQVIA Holdings Inc.'s (NYSE:IQV) CEO Pay?Valuation
Is IQVIA Holdings undervalued compared to its fair value and its price relative to the market?
136.26x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: IQV ($151.21) is trading above our estimate of fair value ($98.3)
Significantly Below Fair Value: IQV is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: IQV is poor value based on its PE Ratio (136.3x) compared to the Life Sciences industry average (37.6x).
PE vs Market: IQV is poor value based on its PE Ratio (136.3x) compared to the US market (16.4x).
Price to Earnings Growth Ratio
PEG Ratio: IQV is poor value based on its PEG Ratio (3.3x)
Price to Book Ratio
PB vs Industry: IQV is good value based on its PB Ratio (5.2x) compared to the US Life Sciences industry average (5.9x).
Next Steps
Future Growth
How is IQVIA Holdings forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?
41.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IQV's forecast earnings growth (41.7% per year) is above the savings rate (2.2%).
Earnings vs Market: IQV's earnings (41.7% per year) are forecast to grow faster than the US market (22.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: IQV's revenue (7.7% per year) is forecast to grow slower than the US market (8.8% per year).
High Growth Revenue: IQV's revenue (7.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IQV's Return on Equity is forecast to be high in 3 years time (21.7%)
Next Steps
Past Performance
How has IQVIA Holdings performed over the past 5 years?
4.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IQV has high quality earnings.
Growing Profit Margin: IQV's current net profit margins (1.9%) are lower than last year (2.4%).
Past Earnings Growth Analysis
Earnings Trend: IQV's earnings have grown by 4.3% per year over the past 5 years.
Accelerating Growth: IQV's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: IQV had negative earnings growth (-13.3%) over the past year, making it difficult to compare to the Life Sciences industry average (10.6%).
Return on Equity
High ROE: IQV's Return on Equity (4.3%) is considered low.
Next Steps
Financial Health
How is IQVIA Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: IQV's short term assets ($4.3B) exceed its short term liabilities ($3.9B).
Long Term Liabilities: IQV's short term assets ($4.3B) do not cover its long term liabilities ($13.4B).
Debt to Equity History and Analysis
Debt Level: IQV's debt to equity ratio (208.3%) is considered high.
Reducing Debt: IQV had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: IQV's debt is not well covered by operating cash flow (12.1%).
Interest Coverage: IQV's interest payments on its debt are not well covered by EBIT (2x coverage).
Balance Sheet
Next Steps
Dividend
What is IQVIA Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IQV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IQV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IQV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IQV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: IQV is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IQV's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.7yrs
Average management tenure
CEO
Ari Bousbib (58yo)
3.67yrs
Tenure
US$22,139,776
Compensation
Mr. Ari Bousbib serves as Chairman and Chief Executive Officer at IQVIA Holdings Inc. since October 2016 and also serves as its President. He has been the Chairman, Chief Executive Officer and President of ...
CEO Compensation Analysis
Compensation vs Market: Ari's total compensation ($USD22.14M) is above average for companies of similar size in the US market ($USD11.52M).
Compensation vs Earnings: Ari's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 3.67yrs | US$22.14m | 0.63% $180.7m | |
| Executive VP & CFO | 4.5yrs | US$2.95m | 0.0084% $2.4m | |
| Executive VP | 2.25yrs | US$2.37m | no data | |
| President of Research & Development Solutions | 3.58yrs | US$2.64m | 0.0065% $1.9m | |
| President of Technology & Commercial Solutions | 3.67yrs | US$2.61m | no data | |
| Senior VP | 1.58yrs | no data | no data | |
| Senior VP | no data | no data | no data | |
| Chief Information Officer | 5.5yrs | no data | no data | |
| Senior VP of Investor Relations & Treasury | no data | no data | no data | |
| Senior Vice President of Strategy | no data | no data | no data |
3.7yrs
Average Tenure
55yo
Average Age
Experienced Management: IQV's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 3.67yrs | US$22.14m | 0.63% $180.7m | |
| Independent Director | 3.67yrs | US$282.39k | 0.039% $11.2m | |
| Independent Director | 12.42yrs | no data | no data | |
| Lead Director | 1.92yrs | US$357.39k | 0.0051% $1.5m | |
| Independent Director | 17.42yrs | no data | no data | |
| Independent Director | 3.67yrs | US$334.89k | 0.033% $9.4m | |
| Independent Director | 2.92yrs | US$314.89k | 0.0038% $1.1m | |
| Independent Director | 3.67yrs | no data | no data | |
| Independent Director | 3.67yrs | no data | no data | |
| Independent Director | 1.33yrs | US$274.89k | 0.0016% $450.5k |
3.7yrs
Average Tenure
59.5yo
Average Age
Experienced Board: IQV's board of directors are considered experienced (3.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
IQVIA Holdings Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: IQVIA Holdings Inc.
- Ticker: IQV
- Exchange: NYSE
- Founded: 1982
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$28.876b
- Shares outstanding: 190.96m
- Website: https://www.iqvia.com
Number of Employees
Location
- IQVIA Holdings Inc.
- 4820 Emperor Boulevard
- Durham
- North Carolina
- 27703
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| IQV | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | May 2013 |
| QTS | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | May 2013 |
| 0JDM | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | May 2013 |
| IQV * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | May 2013 |
| IQVH | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | May 2013 |
| I1QV34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH 4 REPR 1 COM | BR | BRL | Jan 2020 |
Biography
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support services; and strategic planning and design services, as well as clinical trial, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company has a strategic alliance with ACCORD-2 to provide single research platform to speed development of new COVID-19 treatments. IQVIA Holdings Inc. serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/06/05 05:41 |
| End of Day Share Price | 2020/06/04 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.